




Exyte Group

Financial Statement 6M/2022 - Summary

August 16th, 2022



Key Figures 6M/2022*



* All figures are unaudited.

¹ Change year-on-year.

² Full-time equivalents as of June 30, 2022.


Figures at a Glance 6M/2022



in € million	Jan. 1 - Jun. 30, 2022	Jan. 1 - Jun. 30, 2021	Growth
Order intake	4,731	3,175	49.0%
Sales	3,363	2,250	49.5%
Gross profit	277	177	56.5%
Gross profit margin in %	8.2	7.9	0.3PP
EBIT	195	119	63.9%
EBIT margin in %	5.8	5.3	0.5PP
Adjusted EBIT	202	122	65.6%
Adjusted EBIT margin in %	6.0	5.4	0.6PP
Group net profit	176	98	79.6%
Group net profit margin in %	5.2	4.4	0.8PP
No. of Employees (FTEs at the end of the period)	8,572	5,440	-
Cash flow from operating activities	479	213	-
Cash flow from investing activities	-11	32	-
Free cash flow	468	245	-
	Jun. 30, 2022	Dec. 31, 2021	
Order backlog	8,249	6,696	23.2%


Key Financials 6M/2022 I

Order intake




- Increase in order intake compared to 2021 driven by a strong client demand, especially in Southeast Asia.
- Substantial order backlog of 8,249 Mio. € is base for future sales growth.

Sales



- Strong increase of sales compared to 2021 due to large scale projects, especially in EMEA and APAC. CPS acquisition adds 85 Mio. € in 6M/2022.

Key Financials 6M/2022 II



- Adjusted EBIT in 6M/2022 has grown to 202 Mio. € with ATF projects as the main margin contributor.

- Following the EBIT growth, adjusted EBITDA improved to €222 Mio. € in 6M/2022.

1) For explanation of adjusted EBIT, please see "Earnings Performance."


Order Intake by Region 6M/2022

Order intake by region¹

in € million

	6M/2022	6M/2021
APAC	3,023	1,214
EMEA	905	1,695
AMER	459	120
T&S	552	214

in % (previous year)



¹ Before consolidation of the regions.

High order intake

- Major increase in order intake on a year-on-year comparison, with APAC being the largest contributor to the Group's order intake, followed by EMEA.
- Increase of order intake in APAC due to major project awards in China, Singapore, Malaysia and Taiwan.
- Order Intake in AMER is higher than 6M/2021 due to a major project award from a confidential client.
- T&S order intake contribution more than doubled compared to the first six months last year driven by CPS acquisition.

Order Intake by Business Segment 6M/2022

Strong growth of ATF business


- The ATF business segment remains the strongest segment of Exyte with a share of 88.5% in order intake. Significant projects were awarded in Malaysia, China and the US.
- In BLS business segment, Exyte won a large EPC project for building a mRNA competence center in Germany.
- The continuing success of DTC is due to major projects booked in Taiwan and Israel.

Order intake by business segment

in € million

	6M/2022	6M/2021
ATF	4,186	2,667
BLS	283	337
DTC	233	158
RSB	28	13

in % (previous year)




Sales by Region 6M/2022

Sales by region¹

in € million

	6M/2022	6M/2021
APAC	1,862	659
EMEA	1,044	1,232
AMER	202	245
T&S	360	182

in % (previous year)



¹ Before consolidation of the regions.

APAC and T&S with strong performance

- APAC with strong sales increase especially in Singapore, Malaysia and China.
- EMEA's performance remains on a high level, contributed by large projects in Ireland, Germany and Israel.
- T&S sales nearly doubled compared to 6M/2021.

Sales by Business Segment 6M/2022

ATF continues to be the main growth driver


- Due to substantial new and ongoing projects in all regions, the ATF business segment continues to grow year-on-year.
- The BLS business segment increased its sales compared to 6M/2021 due to major projects in Singapore and Malaysia.
- The strong increase in sales of the DTC business segment is driven by several projects in Israel and Germany.

Sales by business segment

in € million

	6M/2022	6M/2021
ATF	2,920	1,971
BLS	291	170
DTC	114	59
RSB	37	50

in % (previous year)



Earnings Performance 6M/2022



Adjusted EBIT¹

in € million

	6M/2022	6M/2021
Reported EBIT	195.1	118.7
Adjustments	6.7	3.0
of which due to restructuring measures	1.7	1.8
of which COVID-19 related adjustments	0.3	0.3
of which other adjustments	4.7	0.9
Adjusted EBIT¹	201.8	121.7

Profitability improved

- Adjusted EBIT¹ (adjusted earnings before interest and taxes) increased above 6M/2021.
- The adjusted EBIT margin improved to 6.0% in 6M/2022; 0.6PP higher than 6M/2021.

1) Adjusted EBIT is defined as the result from operating activities (earnings before interest and tax; EBIT) adjusted for income or expenses deriving from non-recurring effects. EBIT adjustments result from income or expenses related to the Exyte Group's reorganization, costs of restructuring measures, costs incurred due to site closures and relocations, effects on earnings from purchase price allocations or other income or expenses that are non-recurring in nature or are incurred outside the normal course of business, as well as COVID 19-related effects. Adjusted EBIT is used to determine profitability excluding non-recurring positive or negative effects, thus ensuring comparability between different reporting periods.

Outlook Financial Year 2022



Geopolitical tensions and economic uncertainties are affecting the global economy. Further disruptions in supply chains and negative impacts deriving from COVID-19 and other developments can not be completely ruled out going forward.

We expect to outperform our financial targets reaching annual sales of almost €7.0 billion by the end of 2022. In accordance with the increase in targeted sales, a rise in adjusted EBITDA and adjusted EBIT is expected – envisaging a forecasted adjusted EBITDA of approximately €450 million, respectively an adjusted EBIT of above €400 million. Incoming orders in 2022 are expected to be on a comparable high level as in 2021.

This presentation contains forward-looking statements that reflect our current view about future business and financial performance as well as future events or developments. Forward-looking statements are characterized by the use of words such as “expect,” “intend,” “plan,” “predict,” “assume,” “believe,” “estimate,” “anticipate,” and similar expressions. These statements are based on current expectations and assumptions made by the executive management of Exyte Group and are subject to many risks and uncertainties which are mainly beyond Exyte’s control. Should any of these risks or uncertainties materialize or any expectations or assumptions prove to be incorrect, the actual future results may be materially different from those described explicitly or implicitly in the relevant forward-looking statement. Therefore, Exyte does not guarantee any of these forward-looking statements and neither intends nor assumes any obligation to update or revise those in case of developments which differ from those anticipated.

Exyte Group accepts no liability for the accuracy and completeness of information provided in this presentation.



Exyte
René Ziegler
Corporate Communications & Investor Relations
Löwentorbogen 9b
70376 Stuttgart
Germany

T +49 711 8804 4606
ir@exyte.net